Detalhe da pesquisa
1.
Dalcetrapib and anacetrapib increase apolipoprotein E-containing HDL in rabbits and humans.
J Lipid Res
; 64(1): 100316, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36410424
2.
Dalcetrapib and anacetrapib differently impact HDL structure and function in rabbits and monkeys.
J Lipid Res
; 58(7): 1282-1291, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28515138
3.
Cholesteryl ester transfer between lipoproteins does not require a ternary tunnel complex with CETP.
J Struct Biol
; 194(2): 191-8, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26876146
4.
Adenylyl Cyclase 9 Polymorphisms Reveal Potential Link to HDL Function and Cardiovascular Events in Multiple Pathologies: Potential Implications in Sickle Cell Disease.
Cardiovasc Drugs Ther
; 29(6): 563-572, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26619842
5.
Statin-induced decrease in ATP-binding cassette transporter A1 expression via microRNA33 induction may counteract cholesterol efflux to high-density lipoprotein.
Cardiovasc Drugs Ther
; 29(1): 7-14, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25749868
6.
The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial.
Eur Heart J
; 35(27): 1792-800, 2014 Jul 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-24639426
7.
Evidence for a role of CETP in HDL remodeling and cholesterol efflux: role of cysteine 13 of CETP.
Biochim Biophys Acta
; 1831(11): 1644-50, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23872476
8.
Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study.
Am Heart J
; 163(3): 515-21, 521.e1-3, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22424025
9.
Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
Curr Opin Lipidol
; 22(4): 288-95, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21587074
10.
Red Blood Cell Membrane Cholesterol May Be a Key Regulator of Sickle Cell Disease Microvascular Complications.
Membranes (Basel)
; 12(11)2022 Nov 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36422126
11.
Multidimensional profiling of plasma lipoproteins by size exclusion chromatography followed by reverse-phase protein arrays.
J Lipid Res
; 52(12): 2323-2331, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21971713
12.
Inhibition of the 3CL Protease and SARS-CoV-2 Replication by Dalcetrapib.
ACS Omega
; 6(25): 16584-16591, 2021 Jun 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34235330
13.
Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib: Clinical Paradigm and Molecular Mechanisms in Precision Cardiovascular Medicine.
Circ Genom Precis Med
; 14(2): e003219, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33794646
14.
Modulating cholesteryl ester transfer protein activity maintains efficient pre-ß-HDL formation and increases reverse cholesterol transport.
J Lipid Res
; 51(12): 3443-54, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-20861162
15.
Will Lipidation of ApoA1 through Interaction with ABCA1 at the Intestinal Level Affect the Protective Functions of HDL?
Biology (Basel)
; 4(1): 17-38, 2015 Jan 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-25569858
16.
Potential Signal Transduction Regulation by HDL of the ß2-Adrenergic Receptor Pathway. Implications in Selected Pathological Situations.
Arch Med Res
; 46(5): 361-71, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26009249
17.
Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib.
Circ Cardiovasc Genet
; 8(2): 372-82, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25583994
18.
Effect of compounds affecting ABCA1 expression and CETP activity on the HDL pathway involved in intestinal absorption of lutein and zeaxanthin.
Lipids
; 49(12): 1233-43, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25300953
19.
Treatment of low HDL-C subjects with the CETP modulator dalcetrapib increases plasma campesterol only in those without ABCA1 and/or ApoA1 mutations.
Lipids
; 49(12): 1245-9, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25281277
20.
Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
J Clin Lipidol
; 7(5): 414-22, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24079282